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Abstract
Background: The International Organization for Stand-
ardization (ISO) 15189  standard provides recommenda-
tions for the postexamination reporting phase to enhance 
quality in clinical laboratories. The purpose of this study 
was to encourage a broad discussion on current reporting 
practices for molecular diagnostic tests by conducting a 
global survey of such practices.
Methods: The International Federation of Clinical 
Chemistry and Laboratory Medicine’s Committee for 
Molecular Diagnostics (IFCC C-MD) surveyed labora-
tories on selected ISO 15189 recommendations and 
topics. The survey addressed the following aspects: (1) 
laboratory demographics, (2) report format, (3) result 
reporting/layout, (4) comments in report and (5) inter-
pretation and clinical decision-making information. 
Additionally, participants indicated categories needing 
standardization.
Results: Sixteen responses from laboratories located in 
Asia, Europe, the Middle East, North America and South 
America were received. Several categories yielded 100% 
agreement between laboratories, whereas other catego-
ries had less than or equal to 50% concordance. Partici-
pants scored “nomenclature” and “description of method-
ologies” as the two most frequently cited aspects needing 
standardization.
Conclusions: The postexamination phase requires exten-
sive and consistent communication between the labora-
tory, the healthcare provider and the end user. Surveyed 
laboratories were most likely to follow explicit ISO 15189 
recommendations vs. recommendations when the term(s) 
“where appropriate or where applicable” was used. Inter-
pretation and reporting of critical values varied among 
participants. Although the outcome of this study may not 
fully represent the practices of all molecular testing labora-
tories in countries around the world, the survey identified 
and specified several recommendations that are require-
ments for harmonized reporting in molecular diagnostics.
Keywords: clinical genomics; infectious diseases; 
 inherited diseases; ISO 15189; molecular pathology; non-
invasive prenatal testing; oncology; pharmacogenomics; 
precision medicine diagnostics; transplantation.
Introduction
Molecular diagnostic test results facilitate patient manage-
ment by providing the healthcare provider with actionable 
information. Improving patient care requires implementa-
tion of quality management systems and standardized tech-
nical practices by the medical laboratory. These practices 
focus mainly on preexamination, examination and postex-
amination processes (formerly referred to as preanalytic, 
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analytic and postanalytic processes) [1]. Although many 
guidance documents are available, the International 
Organization for Standardization (ISO) 15189  standard 
(2012) was most frequently cited by clinical laboratories 
in the previous survey conducted by the International 
Federation of Clinical Chemistry and Laboratory Medicine 
Committee for Molecular Diagnostics (IFCC C-MD) [1–6]. In 
order to educate and support standardization for molecu-
lar diagnostic testing, the IFCC-MD previously published a 
case-based review that addressed preexamination factors 
that could affect molecular diagnostic assay results [2]. 
As a follow-up to this effort, the IFCC C-MD conducted a 
survey of laboratories performing molecular diagnostic 
tests to determine reporting practices. This study pro-
vided baseline data on current reporting practices used by 
molecular diagnostic laboratories. In addition, data from 
the study identified several aspects of reporting that could 
be improved through standardization. The findings from 
this study aim to encourage a broad discussion on current 
reporting practices in molecular diagnostics.
Survey methodology
A survey was designed to capture data on reporting prac-
tices for molecular diagnostics through a collaborative 
process with an international molecular diagnostic expert 
panel. Questions were derived from the ISO 15189 stand-
ard section (specifically sections 5.8 and 5.9 Reporting of 
Results and Release of Results) and by the expert panel. 
Some questions are not required by the ISO standard 
and may not currently be part of best practice guidelines 
nor were formally recommended by Health-Technology-
Assessment (HTA) bodies. These additional questions were 
deemed important to the IFCC C-MD because they pro-
vided insight into the trends and novel aspects associated 
with reporting molecular diagnostic results. The survey 
for molecular reporting practices addressed the following 
sections: (1) laboratory demographics, (2) report format, 
(3) result reporting/layout, (4) comments in report and (5) 
interpretation and clinical decision making information. 
Additionally, participants were asked to designate areas of 
molecular reporting that need standardization. Surveyed 
laboratories included all members of the IFCC C-MD, the 
IFCC network of molecular centers and molecular diag-
nostic laboratories identified by committee members [7, 8]. 
IFCC C-MD members were nominated by regional clinical 
chemistry organizations to represent molecular diagnos-
tics. Laboratories seeking to be designated an IFCC Network 
of Molecular Diagnostic Centers must obtain approval by 
the IFCC C-MD [9]. The survey consisted of 69 questions 
and had both multiple choice and open answer formats 
(Supplementary Material). The survey took approximately 
45 minutes to complete The data were collected using Sur-
veymonkey.com using an link embedded in an e-mail [10]. 
Over 30 laboratories were invited by e-mail to participate. 
All participants were asked as part of the survey to identify 
the specific area(s) of molecular diagnostics as part of the 
inclusion criteria of the survey.
Results
Survey participant demographics
In order to ascertain laboratory demographics, several 
questions addressed accreditation, guidance documents, 
country, specialization, etc. Figure 1 illustrates the molec-
ular subspecialties reported by the survey participants. 
Some laboratories reported more than one area of molecu-
lar diagnostics. Inherited disease testing was performed 
by 75% of respondents followed by personalized medi-
cine/precision diagnostics, oncology, infectious disease 
testing, pharmacogenomics, non-invasive prenatal testing 
and transplantation. One laboratory responding as “other” 
stated that they performed testing of in vitro diagnostic 
kits on behalf of their national ministry of health. The 
second laboratory responding as “other” stated plans to 
implement oncology and precision diagnostics in the near 
future. The regions represented in the survey included 
Europe (France, Germany and Slovakia), North America 
(Canada, Mexico and United States of America) and South 
America (Paraguay), Asia (China-Hong Kong, India and 
Japan) and the Middle East (Iran and Israel). Some labora-
tories were located in regions that did not require accredi-
tation by governmental or provincial regulatory entities. 
Not all laboratories were required by their health jurisdic-
tion to be accredited by a governmental agency, but all 
laboratories reported using standards/guidelines to insure 
patient care for molecular testing. Standards, accredit-
ing/certifying organizations and guidance documents are 
listed in Tables 1 and 2, respectively. Additional resources 
identified by the IFCC C-MD were added following review 
of the data for these tables.
Report format
Laboratory and patient demographics
The laboratory can define the format in which it chooses 
to report patient results. Laboratories use the following 
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mechanisms to release data: paper/faxed (also known as 
“hard” copies) copies, electronic reports to the health-
care provider, electronic reports to electronic medical 
record (EMR), web-based reporting and reports directly 
to patient.  Some laboratories use a combination of the 
above.
The format of the report should provide identifying 
information regarding both the patient and the laboratory 
performing the test. All survey participants stated that 
the identity of the laboratory, location and address was 
included in the molecular diagnostic report. This infor-
mation provides the healthcare provider with the ability 
to contact the laboratory if necessary. Report design may 
repeat selected information on every page of the report. 
For example, ISO 15189 recommends that the patient 
name and the location of the patient be included on every 
page. The patient location may be interpreted as that of 
a clinic or inpatient facility. All surveyed laboratories 
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Figure 1: Subspecialties of molecular diagnostic laboratories participating in the survey.
The number of laboratories reporting specific areas of specialization is listed above each category.
Table 1: Considered standards, accreditation and certifications 
bodies.
College of American Pathologists (CAP) [11]
Clinical Laboratory Improvement Amendments (CLIA) [12, 13]
Comité Français ď Accréditation (COFRAC) [14]
Deutsche Akkreditierungsstelle (DAkkS) [15]
European Accreditation (EA)a [16]
Health Reference Laboratory, Ministry of Health of IRAN [17]
International Accreditation Foruma (IAF) [18]
International Laboratory Accreditation Cooperationa (ILAC) [19]
International Organization of Standardization (ISO) [20]
National Accreditation Board of Testing and Calibration Laboratories 
(NABL) [21]
National Pathology Accreditation Advisory Council (NPAAC) via 
National Association of Testing Authorities, Australia (NATA) [22]
Netherlands Institute for Accreditationa (NIAZ) [23]
Slovak National Accreditation Service (SNAS) [24]
aOrganizations were not reported in the survey but were added by 
authors for completeness.
Table 2: Considered organizations providing standards and guid-
ance for molecular diagnostic laboratories.
American College of Medical Genetics (ACMG) [25]
Association of Clinical Genetic Science (ACGS)a [26]
Association for Molecular Pathology (AMP)a [27]
Australian Government Department of Health Therapeutic Goods 
Administration [28]
Canadian Standards Associations (CSA) [29]
College of American Pathologists (CAP) [11]
Comité Français ď Accréditation (COFRAC) [14]
Clinical Laboratory Standardization Institute (CLSI) [30]
European Society for Human Genetics (ESHG)a [31]
Japanese Committee for Clinical Laboratory Standards (JCCLS) [32]
International Organization of Standardization (ISO) [20]
International Federation for Clinical Chemistry and Laboratory 
Medicine (IFCC) [7]
Israel Health Ministry Standardization [33]
National Accreditation Board of Testing and Calibration Laboratories 
(NABL) [21]
National Pathology Accreditation Advisory Council (NPAAC) [22]
The Organisation for Economic Co-operation and Development 
(OECD)a [34]
Richtlinie der Bundesärztekammer; German Chamber of  
Physicians [35]
Swiss Society of Medical Genetics (SGMG)a [36]
aOrganizations were not reported in the survey but were added by 
authors for completeness.
Brought to you by | Erasmus University Rotterdam
Authenticated
Download Date | 4/9/19 11:34 AM
Payne et al.: Toward harmonization of clinical molecular diagnostic reports      81
reported that the patient name was included on every 
page of the report. Two respondents (13%) stated that 
their molecular diagnostic report did not include the loca-
tion of the patient on every page (Table 3). Similarly, ISO 
15189 recommends including the name and contact infor-
mation from the healthcare provider on the report. Com-
pliance was 81% for this recommendation. Inclusion of 
the patient location (such as the clinic or outpatient facil-
ity) on all pages of the report ensures that each page can 
be delivered to the healthcare provider. For this reason, 
reports should be numbered and include the total number 
of pages contained in the report (such as page 1 of 2). So-
called “hard copies” or faxed copies of multipage reports 
are at risk of being incomplete if pages become separated 
from each other during the reporting process. Even blank 
pages generated during the process should be included 
in the report to assure that the complete report has been 
delivered to the healthcare provider that ordered the 
test(s). Eighty-seven percent of laboratories state the total 
number of pages in their report. The IFCC C-MD requested 
information inquiring whether laboratories included two 
unique patient identifiers in their reports. Reports includ-
ing two unique identifiers (such as patient name and 
date of birth) improve the process that correct results are 
delivered to patients with the same or similar names, an 
aspect that is particularly important for studies on related 
individuals. Eighty-eight percent (n = 14) of laboratories 
included two unique identifiers in their report.
Sample demographics
Quality and interpretation of test results can be affected 
by auxiliary information such as date and time of speci-
men collection. This information enables the laboratory to 
identify potential preexamination issues that could impact 
reportable results or interpretation [2]. For instance, delays 
in receiving the specimen could render the specimen unac-
ceptable. Date of collection also permits the healthcare 
provider to monitor test results that vary with treatment. 
Compliance with the date of collection was 88%, whereas 
compliance with the time of collection was 75%. Includ-
ing the time of collection is an example of an ambiguous 
recommendation because the specific recommendation 
states “…time, when available and relevant to patient 
care”. Including the time of collection does not universally 
impact the quality of a molecular result or its interpreta-
tion. However, the time of collection may be required for 
test interpretation if treatment is started before or after 
specimen collection. For instance, molecular levels of 
analytes such as tumor biomarkers associated circulat-
ing cell free DNA (cfDNA) or infectious agents may change 
Table 3: Statistics on surveyed laboratories responding to selected ISO 15189 recommendations.
Section   Selected ISO 15189 recommendationsa   Yes  No. of 
responders
  Percentage
  The laboratory report should include:      
5.8.2.a   Comment for sample quality that might compromise examination results   13  15  87
5.8.3.b   The identification of the laboratory, location and addressb   16  16  100
5.8.3.d   Patient identification on each page of the report   16  16  100
5.8.3.d   Patient location on each page of the report   14  16  88
5.8.3.e   Name or unique identifier of the requester and the requester’s contact details   13  16  81
5.8.3.f   Date of the primary sample collection   14  16  88
5.8.3.g   Type of primary specimen   14  16  88
5.8.3.o   Date of the report   16  16  100
5.8.3.o   Time of release (if not contained in the report, readily available when needed)   13  16  81
5.8.3.p   Page numbers to total page number (for example, page 1 of 5)   13  15  87
5.8.3.m   Identification of examinations undertaken as part of a research or development program 
and for which no specific claims on measurement performance are available
  3  15  20
5.8.3.n   Identification of the person(s) reviewing the results and authorizing release of report   10  15  67
5.8.3.n   If identification of the person(s) reviewing the results and authorizing release of report is not 
contained in the report, this information is readily available when needed
  7  7  100
5.9. Note 1   For results of some examinations (e.g. certain genetic or infectious disease examinations), 
special counseling may be needed. The laboratory should endeavor to see that results with 
serious implications are not communicated directly to the patient without the opportunity for 
adequate counseling
  8  14  57
a©ISO. This material is excerpted from ISO 15189:2012 with permission of the American National Standards Institute (ANSI) on behalf of ISO. 
Copies of the standard can be purchased from ANSI at https://webstore.ansi.org. All rights reserved. bISO only requires the identification of 
the laboratory.
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following treatments such as chemotherapy, transfusion 
or antiviral/antibiotic administration. The date that the 
report was released was reported by 100%, whereas labo-
ratories who also included the time of the report was 81%. 
The inclusion of the time of the report should be available 
to the provider if not included on the report according to 
ISO 15189. For a quality monitoring perspective, tracking 
the date and time of release of test results could be valu-
able metrics used to assess sample processing. Interpreta-
tion of laboratory results by the healthcare provider may be 
influenced by the specimen type, and for this reason, spec-
imen type should be included in the report. For instance, 
a healthcare provider may request the same test on bone 
marrow and peripheral blood for molecular monitoring of 
hematologic disorders. Eighty-eight percent of laborato-
ries included the specimen type on reports. Although not 
included in the ISO 15189 recommendations for report-
ing, the surveyed laboratories were asked if the specific 
collection media (or device) was included in the report. 
A lower number of laboratories (56%) included the speci-
men collection media or device on the report. Molecular 
results and interpretation can be affected by the collection 
method, as exemplified by the unsuitability of heparinized 
blood samples in some analytical systems.
International diagnostic codes
Another question that was asked by the IFCC C-MD but 
not required by ISO 15189 inquired if laboratories included 
international diagnostic codes in the report. A minority of 
laboratories (38%) used the World Health Organization 
(WHO) designated International Classification of Diseases 
[ICD-10] codes and/or Online Mendelian Inheritance in 
Man (OMIM®) codes as references for the clinical indi-
cations/disease in the report [37, 38]. For example, the 
ICD-10 code for BCR-ABL1 positive Chronic Myeloid Leu-
kemia (CML) is C92.1, whereas the OMIM code is 608232. 
Clinical classifications in the report support interpreta-
tion of the molecular results. In some instances, testing 
performed on a specimen using a correct diagnostic code 
provides evidence of appropriate test utilization and can 
aid interpretation. In some locales, discrepancies between 
the diagnostic code and the test result may prevent reim-
bursement for the test.
Molecular diagnostic test methodology
Molecular methods differ in their analytic and clinical 
performance characteristics that can negatively impact 
commutability of results. Describing the molecular method 
in the report provides information, aids interpretation of 
test results and enables identification of samples which 
may require a retrospective reanalysis where methods are 
ultimately deemed to be unreliable (e.g. based on profi-
ciency testing). The ISO 15189 recommendation for includ-
ing the measurement/examination method in the report is 
ambiguous in that the phrase “where appropriate” accom-
panies the recommendation. Although this recommenda-
tion is open to interpretation, 94% (n = 15) of laboratories 
identified the methodology in the report. Laboratories 
reporting the method in the body of the report were 88% 
[n = 14]. Other locations for methods description included 
the disclaimer section or a link to an outside source. 
Although  not a recommendation by ISO 15189, some agen-
cies require that the laboratory declare if the method has 
been validated by a regulatory agency, which may be par-
ticularly relevant for laboratory developed tests. Laborato-
ries (specifically 38%) reported if the method was cleared 
or approved by a regulatory agency and included the state-
ment either in the body, disclaimer and/or in a link outside 
of the report. A lower percentage of laboratories (31%) 
disclosed if the laboratory-developed molecular tests were 
validated. Information on the method/examination pro-
vides the healthcare provider the opportunity to interpret 
changes in diagnostic values that may result from techni-
cal artifacts rather than changes caused by pathophysio-
logy of the disorder.
Report size and content
Space restrictions on medical report can be an issue. No 
recommendations on specific font size, report length or 
reporting mechanism (human readable) are mentioned in 
ISO 15189. Some healthcare providers prefer short reports. 
In this survey, reports ranged from one to three pages with 
most laboratories utilizing a one page format (specifically, 
47%) compared to a three page format (specifically, 13%). 
Laboratories may maximize the information on the report 
by altering font size or, as previously mentioned, using links 
to outside information resources such as websites (specifi-
cally disclaimers or statement regarding the measurement 
procedure). Laboratories can elect to emphasize informa-
tion by varying font size. Sixty-three percent of laborato-
ries used different size fonts, color fonts and/or underlined 
words to differentiate “detected” or “affected” from “not 
detected” or “not affected”. By contrast, 67% laboratories 
used the same font size as the rest of the text in the body 
to describe the measurement method. Of the laboratories 
that changed their font size, the font was reduced to size 
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8 and 6. Thirty percent of laboratories include non-human 
readable code (for example, Quick response code [QR] or 
barcodes) on their reports (Figure  2). A balance between 
insuring adequate information for test interpretation and 
readability may be a challenge for laboratories seeking to 
maximize the content of the report while minimizing the 
number of pages for the report.
Laboratories in multilingual countries were surveyed 
to determine the number of languages used to report the 
result. Ninety-three percent of respondents representing 14 
countries used a single language in the report. One country 
reported results in two languages (specifically Persian and 
English). Most countries report in the language spoken by 
the majority of the population. However, some countries 
used English as the reporting language even if the major-
ity of the population spoke a different language. Report-
ing in English in these countries occurred prior to the 
country gaining their sovereign authority (such as when a 
region was occupied or colonized by an English speaking 
country, or if English was the language for medical edu-
cation). ISO 15189 does not have a recommendation for 
selecting the primary language of the report.
Reportable results
Nomenclature
ISO 15189 recommends that results should be unambiguous 
and that standardized nomenclature and units be used in 
reporting results. Standardization of nomenclature, result 
terminology, units, reference sequences and relevant test 
statistical performance (such as clinical and analytical) 
permit the end user to better interpret laboratory results. 
Half the laboratories reported using standardized nomen-
clature in their reports. Not all standardized nomenclature 
is recognizable by the end user; hence, “non-standard-
ized” nomenclature may be added to a report. Two labo-
ratories include both standardized (specifically HUGO) 
and colloquial names in their reports [39]. Another chal-
lenge for reporting is the selection of “positive/negative” 
vs. “detected/not detected”. CLSI MM03 recommends the 
use of “detected” vs. “not detected” for infectious organ-
isms rather than “positive” or “negative” [40]. For inher-
ited diseases, laboratories may use “present/absent” for 
specific gene variants and conclude with a description as 
to whether the genotype is homozygous, heterozygous, 
composite heterozygous and so on. However, if the assay 
is cleared or approved by a regulatory agency, then the 
package insert recommendations for reporting may be fol-
lowed. Thirty-three percent of laboratories included spe-
cific reporting language for assays cleared or approved by 
a regulatory agency in their reports.
Units and reference sequences
ISO 15189 recommendations aim to improve standardi-
zation results through recommending the inclusion of 
international system of units (SI), units traceable to SI 
units or “other appropriate units”. This recommendation 
raises considerable challenges for molecular diagnostics 
reporting as SI units are not available for many analytes. 
Prior to the introduction of the international unit (IU), 
quantification of hepatitis C viral load exemplified the 
heterogeneity of results for different testing methods. 
Although all the results were reported in copies per mil-
liliters, the conversion factors of 0.9, 2.7, 3.4, 3.8 and 
5.2 were required to transform copies/mL to IU for each 
testing methodo logy [41]. Similarly, the introduction of 
the International Scale (IS) unit for BCR-ABL1 quantifi-
cation harmonized reported results across laboratories. 
Prior to the IS unit’s introduction, the Minimal Residual 
Disease (MRD) proficiency testing survey by the College 
of American Pathology (CAP) documented numerous 
reporting units (such as ratio, % ratio, RNA copies, 
cell numbers, % Log BCR-ABL1, copies/mg, log reduc-
tion, etc.). Figure 3 presents the various units used by 
the molecular laboratories (50%) reporting quantitative 
test results. Specific reference sequences may provide a 
control for testing and interpretation of sequence data. 
For laboratories performing sequencing or multiple/
complex single nucleotide polymorphism (SNP) testing, 
69% specified a reference sequence in their reports and 
46% reported variants of unknown or undetermined 
significance (VUS). Relevant analytical and clinical 
performance of the molecular diagnostic assay was not 
always included in the reports issued by participating 
laboratories [42]. For laboratories reporting quantitative 
values, 46% of laboratories included either the Limit of 
Figure 2: Non-human readable codes.
Quick Response Code (QR) for the IFCC C-MD.
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Detection (LOD) and/or the Limit of Quantification (LOQ) 
in their reports. Measures of uncertainty (for example, 
% CV, 95% confidence intervals, etc.) were included in 
reports by 43% of surveyed laboratories. The low adher-
ence rates for these recommendations among surveyed 
laboratories may indicate multiple needs in order to 
standardize reports.
VUS and secondary findings
Variants of undetermined/unknown significance (VUS) 
can be identified with nucleic acid sequencing technolo-
gies [43, 44]. Such variants receive this classification 
when the genotype-phenotype correlation is not known 
or unclear. The clinical significance of these variants may 
not be known at the time of diagnosis but may become 
relevant in the future. A minority of laboratories (46%) 
performing sequence analysis reported VUS. This low 
percentage may reflect the difference between labora-
tories performing complex genotyping using technolo-
gies such as parallel sequencing vs. laboratories offering 
basic genotyping (such as SNP testing for Factor 5 Leiden) 
or targeted infectious disease testing. Additional discus-
sion on interpreting and reporting biocurated VUS will be 
addressed in the interpretation section.
Secondary findings (SF), also known as, inciden-
tal findings (IF), may occur if the laboratory performs a 
test and identifies an organism (or genetic variant) that 
was not requested [44, 45]. For instance, in response to a 
request for Gardnerella vaginalis, a laboratory may erro-
neously perform Neisseria gonorrhoeae (NG) testing. This 
secondary finding could have serious implications if the 
accidental testing identified a medically actionable result. 
Additionally, the laboratory may perform panels of tests 
regardless of whether specific analyte(s)/ measurand(s) 
were requested. The responses for this question were as 
follows: 29% reported SF/IF, 21% did not report SF/IF and 
21% had variable practices depending on the test and test 
result. One laboratory stated that SF were eliminated when 
targeted sequencing was performed. Another laboratory 
identified SF when BRCA1 but not BRCA2 sequencing tests 
(and vice versa) was ordered. In this scenario, the labora-
tory routinely performs and reports sequence results from 
both genes. When a test is accidentally performed due to 
technical or workflow error and the result could impact 
patient care, one participant stated that their laboratory 
would ask the healthcare provider for revised requisition 
for the specific test that was erroneously performed. After 
receipt of the revised requisition, the SF/IF was reported. 
With respect to releasing results from test panels, report-
ing in toto vs. singly had varied responses among surveyed 
laboratories. Fifty-four percent of laboratories performing 
panels reported all results at one time.
Comments on reports
As outlined by the Vasikaran et  al. [46], interpretative 
comments may facilitate aspects of the information hier-
archy by transitioning data to information to knowledge 
to wisdom (DIKW). The DIKW approach to interpretative 
comments on reports can aid clinical decision making. For 
instance, such statements may describe sample quality or 
specimen acceptance/rejection criteria. These comments 
provide ongoing education to healthcare providers. Eighty 
0%
No units are
reported
because results
are qualitative
Genomic
equivalents
International
system of 
units (SI)
International
units (IU)
International
scale (IS)
Copy
number
10%
20%
30%
40%
50%
60%
7
5
4 4
2 2
Figure 3: Units of measure for molecular diagnostics.
The number of laboratories reporting specific units of measure is listed above each category. Laboratories not reporting units did not use 
quantitative tests.
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percent of laboratories provided comments regarding 
inadequate specimen quality and rejection criteria in their 
reports. Table 4 contains comments provided by surveyed 
laboratories. Fifty-three percent of laboratories also stated 
in their reports which specimen types have been validated. 
Most laboratories did not accept testing from unvalidated 
specimens. However, 36% of laboratories who performed 
testing on unvalidated samples types provided a comment 
in the report that the specimen type had been not vali-
dated. Laboratories provided such comments in the body 
(specifically 93%) of the report vs. the disclaimer section 
(specifically 7%). When testing is erroneously performed 
on two different platforms with discordant results, one 
laboratory included a comment that a discordant finding 
was determined using a different platform.
Confusion pertaining to recommendations for so 
called “critical risk results” occurred in the survey [47]. 
Critical risk results generally require immediate medical 
intervention as they indicate a potentially life threaten-
ing disease/condition. Defining critical results or values 
may involve collaboration between the healthcare pro-
vider and the laboratory and may be subjective [47]. Some 
critical values may influence the type and course of treat-
ment. For example, the reporting of the causative agent 
of meningitis/encephalitis or pneumonia would be a criti-
cal risk result. Detection of specific viral and/or bacterial 
entities in cerebral spinal fluid (CSF) from such patients 
triggers significantly different treatment modalities. Other 
examples include the increase in BCR-ABL1  mRNA in 
chronic myeloid leukemia (CML) patients. Detection of 
DPYD*2A/*2A that indicates dihydropyrimidine dehydro-
genase deficiency (DPD) as well as genotyping results that 
predict thiopurine S-methyltransferase (TPMT) deficiency 
might be considered as critical risk results because these 
findings would be important for drug dosage adjustment 
to avoid life-threatening side effects. Without the timely 
reporting of these analyses, the treatment may be delayed. 
Although there was confusion regarding this question, 
47% of laboratories stated that they reported critical risk 
results. Some laboratories designated the critical result 
in bold font, others had a comment “critical results,” 
whereas others had internal processes to contact the 
primary healthcare provider and hospital personnel. 
Twenty-seven percent of laboratories reported that the 
tests that were offered did not qualify as “critical results”.
Interpretation and clinical decision support
The laboratory may provide interpretation and clinical 
support in the report. One of the limitations for providing 
interpretation may be absence or lack of access to relevant 
clinical information. For this reason, the survey requested 
participants to comment whether the report stated that the 
interpretation of the result required clinicopathological 
correlation. Fifty-three percent of laboratories responded 
that their report included this language. Laboratories 
included this statement in the body of the report (50%), 
disclaimer (38%) or website (13%).
Sixty-seven percent of laboratories included result 
interpretation in their reports. Seventy percent of laborato-
ries performing tests for multiple single nucleic polymor-
phisms (SNP) provided interpretation for each SNP along 
with the interpretation of the entire gene panel in their 
report. For example, pharmacogenetic testing for multiple 
SNPs in CYP2D6 may be reported individually and with a 
final interpretation (such as CYP2D6 Poor Metabolizer). 
Interpretation may require algorithms. Fifty percent of lab-
oratories using algorithms for interpreting results provide 
access to the reference either directly in the report, via a 
link or by providing the algorithm upon request. Specific 
clinical advice was routinely provided by 40% of labora-
tories. One laboratory would provide clinical guidance 
in limited scenarios such as the presence of an abnormal 
karyotype. Biological reference intervals, clinical decision 
points or diagrams supporting clinical decision were pro-
vided by 40% of laboratories; however, many laborato-
ries did not perform quantitative testing making this ISO 
15189 recommendation not applicable for some molecular 
testing. Although not a recommendation by ISO 15189, 
60% of laboratories provided  previous molecular findings 
from the patient in the report. For example, some labora-
tories include prior molecular results for high risk human 
papillomavirus (HPV), herpes simplex virus (HSV) and 
Trypanosoma cruzi. Twenty-six percent of laboratories 
include results derived as part of a research program with 
Table 4: Examples of specimen comments included in molecular 
laboratory reports.
Poor specimen quality or quantity
 – Low DNA quality, low DNA quantity
 – The result was inconclusive due to the lack of sufficient cellular-
ity. Recommend recollection and retesting
 – The testing could not be performed due to the specimen not 
having sufficient quantity (QNS). Recommend recollection and 
retesting
 – ATTENTION: Results could have been compromised by low 
sample quality. We recommend testing a new sample
Wrong specimen type
 – Only a peripheral blood is acceptable
Specimen viability compromised
 – Hemolysis was observed to this Blood
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one laboratory stating that the participants were part of a 
clinical research trial. Seventy-three percent of laborato-
ries also stated the person(s) reviewing the final results as 
part of the report. Some molecular diagnostic test results 
(such as some genetic or infectious disease results) may 
require counseling with the patient. Fifty-seven percent of 
laboratories report that measures are taken not to provide 
the information to the patient directly. One such measure 
includes releasing the information directly to the health-
care provider.
Interpreting and managing variants of undetermined/
unknown significance (VUS) is challenging. One approach 
is to biocurate the sequence with periodic review. Biocu-
ration with review permits the laboratory to identify and 
report clinically significant outcomes associated with the 
variant [48]. Of the laboratories performing biocuration, 
the review was performed once every 3 months (n = 1), 
once a year (n = 2), once every 3 years (n = 1) and at differ-
ent times as clinically indicated for the individual patient. 
The laboratories would release a revised report if the 
variant became clinical significant.
Needs assessment
Survey participants were also asked to select areas or 
topics they considered needing standardization. Partici-
pants were permitted to designate multiple areas or topics. 
Nomenclature and description of methodology were most 
frequently cited by 80% (n = 12) and 72% (n = 11) of survey 
respondents, respectively (Figure 4). Sixty percent (n = 9) of 
the laboratories stated a need to standardize management 
of VUS report content with 47% (n = 7) expressing a need 
for standardization of result and interpretative content. 
Reporting aspects as divergent as the use of critical values 
and units of measure were viewed by 40% (n = 6) of labo-
ratories as needing harmonization. Even the least cited 
category of “format” was indicated as an area needing 
standardization by 30% (n = 5) of laboratories. All catego-
ries generated multiple requests for standardization. In 
addition, each participant reported at least four or more 
aspects of the molecular report requiring standardization. 
This feedback underscores the current heterogeneity of 
reports and the desire of laboratories to seek standardiza-
tion in all aspects of molecular diagnostic reports.
Discussion
Standardization of patient care involving molecular diag-
nostics occurs when laboratories follow similar guidelines 
and processes. In this survey, the IFCC C-MD selected rec-
ommendations from ISO 15189 pertaining to the reporting 
phase for the postexamination process of testing and added 
questions to generate a broader discussion on not yet 
0%
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definition
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Figure 4: Self reported areas requiring standardization.
The number of laboratories reporting specific areas is listed above each category.
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standardized reporting practices. Because the maximum 
participation rate was 16 and some regions (such as South 
America) had a single country respond, the outcome may 
not fully represent the practices in the many molecular 
testing laboratories and countries around the world. Addi-
tional bias may be associated with the selection of partici-
pating laboratories as these laboratories are internationally 
recognized for their experience with performing molecular 
diagnostic tests. Given these caveats, the surveyed labo-
ratories followed explicit recommendations of ISO 15189, 
section 5.8 and 5.9.1, at rates that were typically greater than 
80%. However, ISO 15189 also contains numerous recom-
mendations with the phrases “where appropriate”, “where 
applicable”, “when relevant to patient care” that may 
make standardization of reporting practices for molecular 
results difficult. The survey was extensive and appears to 
have lost one initial participant during the process. Future 
surveys will be more concise and will clarify questions with 
examples. Questions pertaining to “critical risk values” 
for molecular diagnostics received several comments that 
underscored the absence in standardization for defining 
this term. The advent of non-human, web-based links and 
the use of the reporting language not commonly used in the 
concerned regions present both opportunities and chal-
lenges. Communication advances (i.e. links to websites, 
etc.) allow access to detailed and most current information 
for report components, but they also require the healthcare 
provider and/or patient have access to electronic and soft-
ware tools. All participants reported at least four categories 
(additionally, each category was identified multiple times) 
of the molecular report as requiring standardization. As 
healthcare providers use and merge multiple molecular 
diagnostic reports into an electronic health record (EHR), 
the heterogeneity in report components represents a poten-
tial safety issue for patient management as healthcare pro-
viders attempt to interpret molecular diagnostic findings. 
In conclusion, the survey identified several postexamina-
tion reporting aspects needing standardization and pro-
vides data that will assist professional organizations (such 
as the IFCC C-MD) to educate and support molecular diag-
nostic laboratories.
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